001367 Zhejiang Haisen Pharmaceutical
- 38.95
- +0.69+1.80%
Zhejiang Haisen Pharmaceutical News
Hisense Pharmaceutical (001367.SZ): The company has products involving the use of biosynthesis related technologies such as enzymatic catalytic reactions
Gelonghui, May 7 | Hisense Pharmaceutical (001367.SZ) said on the investor interactive platform that the company has products involving the use of biosynthesis-related technologies such as enzymatic catalytic reactions. This technology has the advantages of high stereoselectivity, mild reaction conditions, good environmental protection, and low comprehensive cost. In order to further enhance the wide application of related technologies in production, the company cooperated with the Jinhua Research Institute of Zhejiang University and others, and related research work is being actively promoted.
Hisense Pharmaceutical (001367.SZ): Net profit of 33.3848 million yuan in the first quarter increased 33.55% year-on-year
Gelonghui, April 24 | Hisense Pharmaceutical (001367.SZ) released its report for the first quarter of 2024, with operating income of 116 million yuan, up 8.27% year on year; net profit attributable to shareholders of listed companies was 33.3848 million yuan, up 33.55% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 32.641 million yuan, up 30.49% year on year; basic earnings per share were 0.49 yuan.
Hisense Pharmaceutical (001367.SZ): Net profit of 105 million yuan in 2023, plans to convert 10 to 4.8 to 5 yuan
Gelonghui, April 22丨Hysen Pharmaceutical (001367.SZ) announced its 2023 annual report. Operating income for the reporting period was 397 million yuan, down 5.99% year on year; net profit attributable to shareholders of listed companies was 105 million yuan, down 2.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 101 million yuan, down 0.14% year on year; basic income per share was 1.68 yuan; it plans to distribute a cash dividend of 5 yuan (tax included) for every 10 shares to all shareholders.
Heisen Pharmaceutical (001367.SZ): Currently, the company does not produce azithromycin
Glonghui, Oct. 23 | An investor asked Heisen Pharmaceutical (001367.SZ) on the investor interactive platform, “Does the company produce azithromycin?” The company replied that the company currently has a product system that mainly uses digestive, antipyretic, analgesic, and cardiovascular APIs, complemented by APIs such as antidepressants and antimicrobials, and is also prepared with special APIs and preparations such as antiviral and non-steroidal anti-inflammatory drugs. Currently, the company does not produce azithromycin.
Hisen Pharmaceutical (001367.SZ) will list 341,600 restricted shares for circulation on October 17
Hisen Pharmaceutical (001367.SZ) announced that the number of shareholders whose share sales restrictions have been lifted this time is 7,711. The explanation...
Heisen Pharmaceutical (001367.SZ): The main products currently under development include APIs and pharmaceutical products
Glonghui, Oct. 10丨Hyssen Pharmaceutical (001367.SZ) said on the investor interactive platform that the main products currently being developed by the company include APIs and pharmaceutical products.
Haisen Pharmaceutical to Invest 3 Billion Yuan on New Factory
Zhejiang Haisen Pharmaceutical (SHE:001367) has earmarked 3 billion yuan on a new factory within the Zhejiang Dongyang Economic Development Zone. The Chinese pharmaceutical ingredients and intermediat
Hisen Pharmaceutical (001367.SZ) signed a letter of intent to invest in a new plant construction project in Dongyang Economic Development Zone
Hisen Pharmaceutical (001367.SZ) issued an announcement. According to relevant documents of the Dongyang Municipal Government, in an effort to promote Zhejiang Hisen...
Hayson Pharmaceutical (001367.SZ): The antidepressant being developed is a paroxetine hydrochloride preparation
GLONGHUI, September 6丨Hyssen Pharmaceutical (001367.SZ) held a performance briefing on September 6, 2023, on “What is the current status of antidepressant drugs developed by the company?” The company replied that the antidepressant products that the company has already listed include escitalopram oxalopram and its formulation, and paroxetine hydrochloride raw material; the antidepressant currently being developed is paroxetine hydrochloride preparation.
Hayson Pharmaceutical (001367.SZ): Not involved in the production and operation of diet pills
Glonghui September 6th 丨 Hyssen Pharmaceutical (001367.SZ) held a performance briefing on September 6, 2023, on “Is the company involved in weight loss drugs?” The company replied that the company was not involved in the production and operation of diet pills during the reporting period.
Hayson Pharmaceutical (001367.SZ): The company is developing a total of 14 products, including 4 pharmaceutical products
Glonghui September 6th 丨 Hyssen Pharmaceutical (001367.SZ) held a performance briefing on September 6, 2023, on “Has the company developed new varieties of formulations?” The company replied that during the reporting period, the company was developing a total of 14 products, including 4 formulation products.
Hyson Pharmaceutical (001367.SZ): Net profit fell 19.45% in the first half of the year to 458.077 million yuan
Glonghui, August 22丨Hyson Pharmaceutical (001367.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 193 million yuan, down 8.50% year on year; net profit attributable to shareholders of listed companies was 458.077 million yuan, down 19.45% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 444,543 million yuan, down 13.96% year on year; basic earnings per share were 0.81 yuan.
Hysen Pharmaceutical (001367.SZ) released first-quarter results, with net profit of 24.9974 million yuan, an increase of 2.57% over the previous year
According to the Zhitong Finance App, Hysen Pharmaceutical (001367.SZ) released a report for the first quarter of 2023, achieving revenue of 107 million yuan, an increase of 14.87% over the previous year. Net profit attributable to shareholders of listed companies was 24.9974 million yuan, an increase of 2.57% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2,5017,400 yuan, an increase of 2.63% over the previous year.
Hysen Pharmaceutical (001367.SZ): The company does not produce specific drugs against influenza viruses
Gelonhui, April 27丨An investor asked Hysen Pharmaceutical (001367.SZ) on the investor interactive platform, “What specific drugs does your company have in fighting the influenza virus?” Hysen Pharmaceutical replied that the company currently has a product system that mainly focuses on digestive, antipyretic and analgesic, and cardiovascular raw materials, supplemented by raw materials such as antidepressants and antimicrobials, and also prepared with special raw materials and formulations such as antiviral and non-steroidal anti-inflammatory drugs. Currently, the company does not produce specific drugs to fight the influenza virus.
Hysen Pharmaceutical (001367.SZ): Mainly developing products such as Avilever as raw materials for antiviral drugs, are currently not used clinically to treat COVID-19
Gelonhui, April 27丨An investor asked Hysen Pharmaceutical (001367.SZ) on the investor interactive platform, “Does your company produce raw materials for the coronavirus?” Hysen Pharmaceutical replied that according to the “Catalogue of Medication for People Infected with COVID-19 (First Edition)” issued by the Beijing Municipal Health Commission in December 2022, metamizole tablets are included in the catalogue, and the company's products include metamizole APIs. At the same time, the company is mainly developing products such as Avilevir as raw materials for antiviral drugs. Currently, they have not been used clinically to treat COVID-19.
Pharmaceutical stocks fluctuated lower, and Pulley Pharmaceuticals fell more than 10%
Glonghui, April 17丨Pulley Pharmaceutical fell more than 10%, Hysen Pharmaceutical fell more than 8%, and Guobang Pharmaceutical, Gilbert, Hanyu Pharmaceutical, and Nanxin Pharmaceutical followed suit.
Haisen Pharmaceutical Surges 77% in Shenzhen Listing Debut
10:21 PM EDT, 04/09/2023 (MT Newswires) -- Zhejiang Haisen Pharmaceutical (SHE:001367) surged 77% when it debuted on the Shenzhen Stock Exchange's main board Monday morning. Shares of the Chinese prod
Express News | The first batch of new shares of Hysen Pharmaceutical under the Main Board registration system triggered a temporary suspension of trading.
Express News | The first batch of 10 IPOs under the Main Board registration system will be listed on April 10:5 on the Shenzhen Stock Exchange and 5 on the Shanghai Stock Exchange
Express News | The first batch of 10 IPOs under the Main Board registration system will be unveiled next Monday
Analysis
Price Target
No Data
